AU2003211042A8 - Use of buckysome or carbon nanotube for drug delivery - Google Patents
Use of buckysome or carbon nanotube for drug deliveryInfo
- Publication number
- AU2003211042A8 AU2003211042A8 AU2003211042A AU2003211042A AU2003211042A8 AU 2003211042 A8 AU2003211042 A8 AU 2003211042A8 AU 2003211042 A AU2003211042 A AU 2003211042A AU 2003211042 A AU2003211042 A AU 2003211042A AU 2003211042 A8 AU2003211042 A8 AU 2003211042A8
- Authority
- AU
- Australia
- Prior art keywords
- buckysome
- drug delivery
- carbon nanotube
- nanotube
- drug
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y30/00—Nanotechnology for materials or surface science, e.g. nanocomposites
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S516/00—Colloid systems and wetting agents; subcombinations thereof; processes of
- Y10S516/901—Substantially pure carbon, e.g. graphite, lamp black, carbon black, fullerenes
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/70—Nanostructure
- Y10S977/734—Fullerenes, i.e. graphene-based structures, such as nanohorns, nanococoons, nanoscrolls or fullerene-like structures, e.g. WS2 or MoS2 chalcogenide nanotubes, planar C3N4, etc.
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T428/00—Stock material or miscellaneous articles
- Y10T428/13—Hollow or container type article [e.g., tube, vase, etc.]
- Y10T428/1352—Polymer or resin containing [i.e., natural or synthetic]
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T428/00—Stock material or miscellaneous articles
- Y10T428/13—Hollow or container type article [e.g., tube, vase, etc.]
- Y10T428/1352—Polymer or resin containing [i.e., natural or synthetic]
- Y10T428/139—Open-ended, self-supporting conduit, cylinder, or tube-type article
- Y10T428/1393—Multilayer [continuous layer]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nanotechnology (AREA)
- Oncology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Materials Engineering (AREA)
- General Physics & Mathematics (AREA)
- Condensed Matter Physics & Semiconductors (AREA)
- Composite Materials (AREA)
- Physics & Mathematics (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pathology (AREA)
- Toxicology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Medical Informatics (AREA)
- General Engineering & Computer Science (AREA)
- Hematology (AREA)
- Virology (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US35685602P | 2002-02-14 | 2002-02-14 | |
US60/356,856 | 2002-02-14 | ||
PCT/US2003/004416 WO2003068185A2 (en) | 2002-02-14 | 2003-02-14 | Use of buckysome or carbon nanotube for drug delivery |
Publications (2)
Publication Number | Publication Date |
---|---|
AU2003211042A8 true AU2003211042A8 (en) | 2003-09-04 |
AU2003211042A1 AU2003211042A1 (en) | 2003-09-04 |
Family
ID=27734694
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2003211042A Abandoned AU2003211042A1 (en) | 2002-02-14 | 2003-02-14 | Use of buckysome or carbon nanotube for drug delivery |
Country Status (6)
Country | Link |
---|---|
US (2) | US7070810B2 (en) |
EP (2) | EP2127680A1 (en) |
JP (1) | JP4676701B2 (en) |
AU (1) | AU2003211042A1 (en) |
TW (1) | TW200307563A (en) |
WO (1) | WO2003068185A2 (en) |
Families Citing this family (63)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9056783B2 (en) | 1998-12-17 | 2015-06-16 | Hach Company | System for monitoring discharges into a waste water collection system |
US7454295B2 (en) | 1998-12-17 | 2008-11-18 | The Watereye Corporation | Anti-terrorism water quality monitoring system |
US8958917B2 (en) | 1998-12-17 | 2015-02-17 | Hach Company | Method and system for remote monitoring of fluid quality and treatment |
US6723299B1 (en) * | 2001-05-17 | 2004-04-20 | Zyvex Corporation | System and method for manipulating nanotubes |
TW200307563A (en) * | 2002-02-14 | 2003-12-16 | Sixty Inc C | Use of BUCKYSOME or carbon nanotube for drug delivery |
US7758889B1 (en) | 2002-07-24 | 2010-07-20 | Luna Innovations Incorporated | Fullerenes in targeted therapies |
US20080193490A1 (en) * | 2002-02-14 | 2008-08-14 | Andreas Hirsch | Use of Carbon Nanotube for Drug Delivery |
US20040166152A1 (en) * | 2002-02-14 | 2004-08-26 | Andreas Hirsch | Use of buckysome or carbon nanotube for drug delivery |
EP1583713B1 (en) | 2003-01-07 | 2009-03-25 | Ramot at Tel Aviv University Ltd. | Peptide nanostructures encapsulating a foreign material and method of manufacturing same |
US8920619B2 (en) | 2003-03-19 | 2014-12-30 | Hach Company | Carbon nanotube sensor |
US20050058675A1 (en) * | 2003-04-10 | 2005-03-17 | Wilson Stephen R. | Fullerene compositions for ameliorating dermatological conditions |
US20050038498A1 (en) * | 2003-04-17 | 2005-02-17 | Nanosys, Inc. | Medical device applications of nanostructured surfaces |
US7972616B2 (en) | 2003-04-17 | 2011-07-05 | Nanosys, Inc. | Medical device applications of nanostructured surfaces |
US7803574B2 (en) * | 2003-05-05 | 2010-09-28 | Nanosys, Inc. | Medical device applications of nanostructured surfaces |
US20060247152A1 (en) * | 2005-05-02 | 2006-11-02 | Russ Lebovitz | Substituted fullerenes and their use as inhibitors of cell death |
US20050288236A1 (en) * | 2003-10-10 | 2005-12-29 | Russ Lebovitz | Substituted fullerene formulations and their use in ameliorating oxidative stress diseases or inhibiting cell death |
US7163956B2 (en) * | 2003-10-10 | 2007-01-16 | C Sixty Inc. | Substituted fullerene compositions and their use as antioxidants |
US7507764B2 (en) * | 2003-10-15 | 2009-03-24 | Tego Biosciences Corporation | Amphiphilic [5:1]- and [3:3]- hexakisadducts of fullerenes |
US20050096509A1 (en) * | 2003-11-04 | 2005-05-05 | Greg Olson | Nanotube treatments for internal medical devices |
US7824660B2 (en) * | 2003-12-05 | 2010-11-02 | Buzatu Dan A | Nanotubes for cancer therapy and diagnostics |
US20060067941A1 (en) * | 2003-12-05 | 2006-03-30 | Secretary, Department Of Health & Human Services | Nanotubes for cancer therapy and diagnostics |
US7608240B2 (en) * | 2003-12-05 | 2009-10-27 | Board Of Trustees Of The University Of Arkansas | Nanotubes for cancer therapy and diagnostics |
DE102004017705A1 (en) * | 2004-04-07 | 2005-11-03 | Leibniz-Institut Für Festkörper- Und Werkstoffforschung Dresden E.V. | Ferromagnetic carbon nanotubes carrying biomolecules, methods of making them, and their use in diagnosis and therapy |
EP2113302A4 (en) * | 2004-05-13 | 2009-12-23 | Univ Hokkaido Nat Univ Corp | Fine carbon dispersion |
JP4618409B2 (en) * | 2004-06-25 | 2011-01-26 | 味の素株式会社 | Oral uremic toxin adsorbent |
US20060051290A1 (en) * | 2004-07-13 | 2006-03-09 | William Marsh Rice University | Short carbon nanotubes as adsorption and retention agents |
WO2006028635A2 (en) * | 2004-09-02 | 2006-03-16 | C Sixty Inc. | Fullerene compositions for ameliorating hearing loss, collateral damage of chemotherapy, or mucositis |
WO2007018562A2 (en) * | 2004-09-22 | 2007-02-15 | Nanolab, Inc. | Nanospearing for molecular transportation into cells |
US7459013B2 (en) * | 2004-11-19 | 2008-12-02 | International Business Machines Corporation | Chemical and particulate filters containing chemically modified carbon nanotube structures |
WO2006078257A1 (en) * | 2005-01-19 | 2006-07-27 | C Sixty Inc. | Substituted fullerene compositions and their use in treatment of shock |
US20090311767A1 (en) * | 2005-04-21 | 2009-12-17 | Chiles Thomas C | Method for molecular delivery into cells using naonotube spearing |
US8246995B2 (en) * | 2005-05-10 | 2012-08-21 | The Board Of Trustees Of The Leland Stanford Junior University | Hydrophobic nanotubes and nanoparticles as transporters for the delivery of drugs into cells |
JP4090496B2 (en) * | 2005-07-01 | 2008-05-28 | 独立行政法人科学技術振興機構 | Method for producing nanocarbon carrier and DDS agent using nanocarbon carrier produced by the method |
JP2007084393A (en) * | 2005-09-26 | 2007-04-05 | National Institute Of Advanced Industrial & Technology | Carotenoid including structure |
ITMI20051913A1 (en) * | 2005-10-11 | 2007-04-12 | Zelens Dermatological Uk Ltd | LIPOSOMAS LOADED WITH FULLERENE AND PROCEDURE FOR THEIR PREPARATION |
GB0520902D0 (en) * | 2005-10-14 | 2005-11-23 | Chowdhury Dewan F H | Nanotubes |
EP1934138A2 (en) * | 2005-10-14 | 2008-06-25 | Dewan Fazlul Hoque Chowdhury | Amphiphilic nanotubes and micelles comprising same for use in the delivery of biologically active agents |
US20080020977A1 (en) * | 2005-11-21 | 2008-01-24 | Russ Lebovitz | Use of Fullerenes to Oxidize Reduced Redox Proteins |
ATE524197T1 (en) * | 2006-05-25 | 2011-09-15 | Univ Wake Forest Health Sciences | HYPERTHERMAL TECHNIQUES AND THEIR THERAPEUTIC APPLICATIONS |
WO2007143558A1 (en) * | 2006-06-01 | 2007-12-13 | William Marsh Rice University | Targeted nanostructures for cellular imaging |
US8501233B2 (en) * | 2007-03-13 | 2013-08-06 | Wake Forest University | Compositions and methods for treating cancer |
EP2173467B1 (en) | 2007-07-13 | 2016-05-04 | The Board Of Trustees Of The Leland Stanford Junior University | Method and apparatus using electric field for improved biological assays |
WO2009018092A1 (en) | 2007-07-27 | 2009-02-05 | The Board Of Trustees Of The Leland Stanford Junior University | Supramolecular functionalization of graphitic nanoparticles for drug delivery |
US9550827B2 (en) | 2007-10-19 | 2017-01-24 | The Regents Of The University Of California | Methods for ameliorating and preventing central nervous system inflammation |
WO2009114089A2 (en) * | 2008-03-03 | 2009-09-17 | Luna Innovations Incorporated | Using fullerenes to enhance and stimulate hair growth |
CA2717497A1 (en) * | 2008-03-03 | 2009-09-17 | Luna Innovations Incorporated | Method for inhibiting the build-up of arterial plaque by administering fullerenes |
US10167572B2 (en) * | 2009-08-07 | 2019-01-01 | Guardian Glass, LLC | Large area deposition of graphene via hetero-epitaxial growth, and products including the same |
US8236118B2 (en) | 2009-08-07 | 2012-08-07 | Guardian Industries Corp. | Debonding and transfer techniques for hetero-epitaxially grown graphene, and products including the same |
US8507797B2 (en) | 2009-08-07 | 2013-08-13 | Guardian Industries Corp. | Large area deposition and doping of graphene, and products including the same |
US10164135B2 (en) * | 2009-08-07 | 2018-12-25 | Guardian Glass, LLC | Electronic device including graphene-based layer(s), and/or method or making the same |
US8808810B2 (en) * | 2009-12-15 | 2014-08-19 | Guardian Industries Corp. | Large area deposition of graphene on substrates, and products including the same |
US8604332B2 (en) | 2010-03-04 | 2013-12-10 | Guardian Industries Corp. | Electronic devices including transparent conductive coatings including carbon nanotubes and nanowire composites, and methods of making the same |
US8460747B2 (en) | 2010-03-04 | 2013-06-11 | Guardian Industries Corp. | Large-area transparent conductive coatings including alloyed carbon nanotubes and nanowire composites, and methods of making the same |
US8518472B2 (en) * | 2010-03-04 | 2013-08-27 | Guardian Industries Corp. | Large-area transparent conductive coatings including doped carbon nanotubes and nanowire composites, and methods of making the same |
ES2374243B1 (en) * | 2010-08-02 | 2012-12-26 | Universidad Castilla-La Mancha | NON-VIRAL VECTORS FOR GENE THERAPY. |
RU2469729C1 (en) * | 2011-08-26 | 2012-12-20 | Учреждение Российской академии медицинских наук Научно-исследовательский институт кардиологии Сибирского отделения РАМН | Medication for destructuring atherosclerotic lesions, formed on walls of blood vessels |
JP2015536319A (en) * | 2012-10-16 | 2015-12-21 | ウィリアム・マーシュ・ライス・ユニバーシティ | Improved nanovector-based drug delivery system to overcome drug resistance |
US10431354B2 (en) | 2013-03-15 | 2019-10-01 | Guardian Glass, LLC | Methods for direct production of graphene on dielectric substrates, and associated articles/devices |
US9593019B2 (en) | 2013-03-15 | 2017-03-14 | Guardian Industries Corp. | Methods for low-temperature graphene precipitation onto glass, and associated articles/devices |
US10145005B2 (en) | 2015-08-19 | 2018-12-04 | Guardian Glass, LLC | Techniques for low temperature direct graphene growth on glass |
ES2577056B2 (en) * | 2016-03-16 | 2017-01-17 | Universidad De Cantabria | Coverage of carbon nanotubes for use as an anchoring system for nano and micrometric devices with therapeutic activity |
US10293054B2 (en) | 2017-02-23 | 2019-05-21 | LivePet, LLC | Lipofullerene-saccharide conjugates and their use as antimetastatic agents for the inhibition of mammalian neoplasms |
CN108863735B (en) * | 2018-07-17 | 2021-06-04 | 河南师范大学 | Synthesis method of [60] fullerene cyclopentanone and [60] fullerene 2-cyclohexenone compounds |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9203037D0 (en) * | 1992-02-11 | 1992-03-25 | Salutar Inc | Contrast agents |
DE4313481A1 (en) | 1993-04-24 | 1994-10-27 | Hoechst Ag | Fullerene derivatives, process for their preparation and their use |
CA2166380A1 (en) | 1993-06-30 | 1995-01-12 | Sandra G. Fitzpatrick-Mcelligott | Method for introducing a biological substance into a target |
US5811460A (en) | 1994-01-24 | 1998-09-22 | The Regents Of The University Of California | Water soluble fullerenes with antiviral activity |
US6162926A (en) * | 1995-07-31 | 2000-12-19 | Sphere Biosystems, Inc. | Multi-substituted fullerenes and methods for their preparation and characterization |
AU5794498A (en) * | 1996-12-10 | 1998-07-03 | Genetrace Systems, Inc. | Releasable nonvolatile mass-label molecules |
DE19807979C2 (en) * | 1998-02-25 | 2003-02-06 | Siemens Axiva Gmbh & Co Kg | Dendrimeric fullerene derivatives, process for their preparation and use as neuroprotective agents |
EP1064310A1 (en) * | 1998-03-18 | 2001-01-03 | University Of Rochester | Macromolecular self-assembly of microstructures, nanostructures, objects and mesoporous solids |
AU3529299A (en) * | 1998-05-07 | 1999-11-23 | Centre National De La Recherche Scientifique-Cnrs | Method for immobilising and/or crystallising biological macromolecules on carbonnanotubes and uses |
US6593137B1 (en) * | 1999-08-31 | 2003-07-15 | The Trustees Of Columbia University In The City Of New York | Antibodies specific for fullerenes |
US6397102B1 (en) * | 2000-07-06 | 2002-05-28 | Ceramoptec Industries, Inc. | Device and method for photoactivated drug therapy |
US6652833B2 (en) | 2000-07-13 | 2003-11-25 | The Regents Of The University Of California | Functionalized active-nucleus complex sensor |
US6984395B2 (en) * | 2001-04-11 | 2006-01-10 | Qlt, Inc. | Drug delivery system for hydrophobic drugs |
TW200307563A (en) * | 2002-02-14 | 2003-12-16 | Sixty Inc C | Use of BUCKYSOME or carbon nanotube for drug delivery |
-
2003
- 2003-02-13 TW TW092102970A patent/TW200307563A/en unknown
- 2003-02-14 JP JP2003567369A patent/JP4676701B2/en not_active Expired - Lifetime
- 2003-02-14 EP EP09169560A patent/EP2127680A1/en not_active Withdrawn
- 2003-02-14 WO PCT/US2003/004416 patent/WO2003068185A2/en active Application Filing
- 2003-02-14 EP EP03739798A patent/EP1476198A2/en not_active Withdrawn
- 2003-02-14 AU AU2003211042A patent/AU2003211042A1/en not_active Abandoned
- 2003-02-14 US US10/367,646 patent/US7070810B2/en not_active Expired - Fee Related
-
2006
- 2006-02-06 US US11/347,906 patent/US20060127470A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
TW200307563A (en) | 2003-12-16 |
US7070810B2 (en) | 2006-07-04 |
WO2003068185A2 (en) | 2003-08-21 |
US20060127470A1 (en) | 2006-06-15 |
JP2006502966A (en) | 2006-01-26 |
WO2003068185A3 (en) | 2003-11-13 |
EP1476198A2 (en) | 2004-11-17 |
JP4676701B2 (en) | 2011-04-27 |
US20030180491A1 (en) | 2003-09-25 |
EP2127680A1 (en) | 2009-12-02 |
AU2003211042A1 (en) | 2003-09-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2003211042A8 (en) | Use of buckysome or carbon nanotube for drug delivery | |
AU2003245757A8 (en) | Vaporizer delivery ampoule | |
EP1487320A4 (en) | Anesthesia drug monitor | |
AU2003295614A8 (en) | Delivery of pharmaceutical agents via the human insulin receptor | |
AU2003299849A8 (en) | Drug delivery apparatus | |
HK1085131A1 (en) | Solid drug for oral use | |
IL174748A0 (en) | Nanoparticles for drug delivery | |
EP1510207A4 (en) | Therapeutic drug for diabetes | |
EP1469812A4 (en) | Oral insulin therapy | |
IL174396A0 (en) | Oral drug delivery system | |
GB2400565B (en) | Nasal drug delivery | |
GB0227135D0 (en) | Therapeutic delivery of carbon monoxide | |
EP1535644A4 (en) | Needle for medical use | |
GB0506809D0 (en) | Drug nebulizer usable with a diagnostic or therapeutic instrument, such as a bronchoscope | |
IL171911A0 (en) | Catheter for uniform delivery of medication | |
GB0228305D0 (en) | Therapeutic composition for respiratory delivery | |
AUPS286302A0 (en) | Medication inhaler | |
AU2003294952A8 (en) | 3,3-dimethyl-8-oxoisoquinolines for medical purposes, methods for the production thereof, medicaments containing said compounds and the use of the same | |
EP1485077A4 (en) | Drug combination therapy | |
GB0318254D0 (en) | Therapeutic delivery of carbon monoxide | |
GB0210020D0 (en) | Medical agent delivery | |
AU2003229137A8 (en) | Medication inhaler | |
GB0206856D0 (en) | Improved medical inhaler | |
GB0203773D0 (en) | Improving drug delivery to the respiratory tract | |
GB0203830D0 (en) | Improving drug delivery to the respiratory tract |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MK6 | Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase |